Show simple item record

dc.contributor.authorSimon, J
dc.contributor.authorKennedy, S
dc.contributor.authorMahon, B
dc.contributor.authorDubey, S
dc.contributor.authorGrant-Klein, R
dc.contributor.authorLiu, K
dc.contributor.authorHartzel, J
dc.contributor.authorColler, B
dc.contributor.authorWelebob, C
dc.contributor.authorHanson, M
dc.contributor.authorGrais, R
dc.date.accessioned2021-02-23T22:40:45Z
dc.date.available2021-02-23T22:40:45Z
dc.date.issued2020-09-20
dc.date.submitted2021-02-01
dc.identifier.urihttp://hdl.handle.net/10144/619882
dc.description.abstractBackground The recent Ebola virus disease (EVD) outbreak in the Democratic Republic of the Congo highlights the sustained threat of EVD morbidity and mortality where healthcare and vaccine delivery are challenging. ERVEBO®, a live recombinant vesicular stomatitis virus (VSV) vaccine containing the Zaire ebolavirus glycoprotein (GP) in place of the VSV GP (rVSVΔG-ZEBOV-GP), was developed by Merck & Co., Inc., Kenilworth, NJ, USA in collaboration with multiple partners to prevent EVD and has been approved for human use in several countries. Methods We pooled data from three Phase 2/3 clinical trials conducted in Guinea (FLW), Sierra Leone (STRIVE), and Liberia (PREVAIL) during the 2013–2016 West African outbreak to assess immune responses using a validated assay in each of the three studies and performed a post hoc analysis by sex, age (18–50 yrs & >50 yrs) and baseline (BL) GP-enzyme-linked immunosorbent assay (ELISA) titer (< 200 & ≥200 EU/ml). The full analysis set (FAS) population included the primary immunogenicity populations (all vaccinated participants with serology data collected within an acceptable day range) from all three trials. The endpoints were total IgG antibody response (EU/mL) measured by the GP-ELISA and neutralizing antibody response measured by the plaque reduction neutralization test (PRNT) to rVSVΔG-ZEBOV-GP at Days 14, 28, 180, and 365 postvaccination. Results In the overall population and in all subgroups, GP-ELISA and PRNT geometric mean titers increased from BL, with most peaking at Day 28 and persisting through Day 365. There were differences between males and females and between participants with BL GP-ELISA < 200 & ≥200 EU/ml. There did not appear to be a difference between age groups. Conclusion These data demonstrate that rVSVΔG-ZEBOV-GP elicits a robust and durable immune response up to 12 months in participants regardless of age, sex, or BL GP-ELISA titer. The higher immune responses observed in females and participants with preexisting immunity are consistent with those described in published literature for other vaccines.en_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.rightsWith thanks to Oxford University Press.en_US
dc.title28. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO™) in Participants by Age, Sex, and Baseline GP-ELISA Titer: A Post Hoc Analysis of Three Phase 2/3 Trialsen_US
dc.identifier.journalOpen Forum Infectious Diseasesen_US
refterms.dateFOA2021-02-23T22:40:46Z


Files in this item

Thumbnail
Name:
Simon et al 2020 28. Immunogenicity ...
Size:
145.5Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record